ArticleBMC cancer2017
CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Genetics in medicine : official journal of the American College of Medical Genetics · 2023Guideline
- Leveraging Northern European population history: novel low-frequency variants for polycystic ovary syndrome.Human reproduction (Oxford, England) · 2022Pooled it
- Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.Molecular diagnosis & therapy · 2018Pooled it
- Cancer spectrum in Mexican patients with the CHEK2 p.(Leu236Pro) variant: a retrospective study.Familial cancer · 2025Article
- Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Cohort profile: a nationwide study in DutchBMJ open · 2024Article
- Screening Familial Risk for Hereditary Breast and Ovarian Cancer.JAMA network open · 2024Article
- Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyondJournal of medical genetics · 2024Article
- Gender-Specific Genetic Predisposition to Breast Cancer:Cancers · 2024Review
- Apocrine Breast Cancer With Psammoma Bodies in a Male Patient.HCA healthcare journal of medicine · 2024Article
- Article
- Analysis of the distinct features of metastasis male breast cancer and its effect on overall survival based on the SEER database compared with female breast cancer.Translational cancer research · 2023Article
- Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population-based observational study.Cancer medicine · 2022Observational
- Male breast cancer: an update.Virchows Archiv : an international journal of pathology · 2022Review
- Genetic predisposition to male breast cancer in Poland.BMC cancer · 2021Article
- Genetic Landscape of Male Breast Cancer.Cancers · 2021Review
- Nomogram Predicts the Role of Contralateral Prophylactic Mastectomy in Male Patients With Unilateral Breast Cancer Based on SEER Database: A Competing Risk Analysis.Frontiers in oncology · 2021Article
- Review
- Identification of novel candidate genes by exome sequencing in Tunisian familial male breast cancer patients.Molecular biology reports · 2020Article
- Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database.Therapeutic advances in medical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral susceptibility genes have been established for female breast cancer, of which mutations in BRCA1 and especially in BRCA2 are also known risk factors for male breast cancer (MBC). The role of other breast cancer genes in MBC is less well understood.
methodsIn this study, we have genotyped 68 MBC patients for the known breast or ovarian cancer associated mutations in the Finnish population in CHEK2, PALB2, RAD51C, RAD51D, and FANCM genes.
resultsCHEK2 c.1100delC mutation was found in 4 patients (5.9%), which is significantly more frequent than in the control population (OR: 4.47, 95% CI 1.51-13.18, p = 0.019). Four CHEK2 I157T variants were also detected, but the frequency did not significantly differ from population controls (p = 0.781). No RAD51C, RAD51D, PALB2, or FANCM mutations were found.
conclusionsThese data suggest that the CHEK2 c.1100delC mutation is associated with an increased risk for MBC in the Finnish population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.